Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Roy Herbst about the ADAURA Trial. ADAURA introduced targeted therapy in the adjuvant setting for early-stage EGFR-positive NSCLC. While we have seen targeted therapy in this space, ADAURA showed DFS rates never seen before and changed the treatment of early-stage lung cancer.

Podcast Hosts:

• Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA  
• Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA 

Podcast Guests: 

• Roy Herbst, MD, PhD, Chief, Medical Oncology, Yale Cancer Center, New Haven, CT, USA